Kwangmyeng Kim

Title: Kwangmyeng Kim: Innovator in Recombinant Albumin Technology

Introduction

Kwangmyeng Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant albumins. His innovative work focuses on enhancing drug delivery systems, which can have a profound impact on medical treatments.

Latest Patents

Kwangmyeng Kim holds a patent for "Recombinant albumins fused with poly-cysteine peptide and the methods for preparing the same." This invention relates to recombinant albumins that have cysteines amplified at both the N-terminal and C-terminal. These modifications improve albumin-drug conjugation efficiency, making it possible to deliver larger amounts of drugs to target tissues effectively. The recombinant albumin also reduces side effects compared to conventional albumin carriers by regulating the amount of drug conjugated to each unit of albumin. Furthermore, this technology can be utilized for novel drug screening and non-invasive real-time diagnosis and treatment of diseases through molecular imaging.

Career Highlights

Kwangmyeng Kim is affiliated with the Korea Institute of Science and Technology, where he continues to advance his research in biotechnology. His work has garnered attention for its potential applications in drug delivery and disease treatment.

Collaborations

Kwangmyeng Kim collaborates with notable colleagues, including Hyung Jun Ahn and Ick Chan Kwon. Their combined expertise contributes to the innovative research being conducted at the Korea Institute of Science and Technology.

Conclusion

Kwangmyeng Kim's contributions to recombinant albumin technology represent a significant advancement in drug delivery systems. His innovative approach not only enhances the efficiency of drug delivery but also minimizes side effects, paving the way for improved medical treatments.